WebOfPharma · Cleaning-validation limits
10 ppm, Therapeutic Dose and HBEL Limits Compared
A practical GMP comparison of concentration-based, dose-based and health-based carryover limits for pharmaceutical cleaning validation.
10 ppm, therapeutic dose and HBEL limits compared is a common search and audit question because the three approaches can produce very different cleaning-validation results. They are not interchangeable formulas. Each answers a different question: how much residue is present by concentration, how much pharmacological exposure might reach the next product, or how much exposure is unlikely to cause harm based on the complete toxicological evidence.
This guide explains the difference in plain language, provides worked calculations, and shows how to select a defensible limit strategy for shared pharmaceutical equipment. The goal is not to apply one number to every product; it is to connect toxicology, process knowledge, equipment design, analytical capability and cGMP decision-making.
At a glance: what each limit means
Concentration rule
10 ppm
Limits previous-product residue to 10 mg per kg of the next product, unless a site defines an equivalent unit basis.
Dose rule
Therapeutic dose
Historically limits carryover to a fraction, commonly 1/1000, of a defined therapeutic dose.
Health basis
HBEL
Uses substance-specific toxicology and pharmacology to set a health-based exposure threshold.
Implementation
MACO
Converts the selected health or concentration criterion into an equipment-specific carryover mass.
The comparison becomes meaningful only when units, product pair, batch size, daily dose, route and equipment surface area are defined. A value that is safe for one product sequence may not be safe or practical for another.
10 ppm, therapeutic dose and HBEL compared
| Approach | Primary basis | Typical calculation concept | Main advantage | Main limitation |
|---|---|---|---|---|
| 10 ppm | Mass concentration in the next product | MACO = 10 mg/kg × next-product batch mass (kg) | Simple, transparent and easy to verify | Does not inherently reflect potency, toxicity, sensitization or route |
| Therapeutic dose | Pharmacological dose relationship | MACO = previous minimum daily dose × next batch mass ÷ (1000 × next maximum daily dose) | Uses dose information rather than only concentration | Can miss non-dose-related hazards and depends on a meaningful dose definition |
| HBEL / PDE / ADE | Substance-specific toxicology and pharmacology | MACO = approved HBEL × next batch mass ÷ next maximum daily dose | Links the limit to adverse-effect evidence and uncertainty | Requires qualified toxicology, current data and careful governance |
| Visual cleanliness | Observable residue | No visible residue under defined inspection conditions | Fast, practical release check | Cannot prove absence of sub-visible chemical residue |
FDA cleaning-validation material describes 10 ppm, a fraction of the normal therapeutic dose and no visible residue as examples discussed in industry; it does not create one universal number for every product or equipment train. Current programs should document a scientific, practical, achievable and verifiable rationale for their acceptance criteria.
What is the 10 ppm cleaning limit?
Ten parts per million means 10 units of previous-product residue for every 1,000,000 equivalent units of next-product mass. In a common mass basis, 10 ppm equals 10 mg/kg, or 10 micrograms per gram. The limit is attractive because it can be calculated without a toxicological report, but that simplicity is also its weakness.
The 2,500 mg result is a concentration-based allowance, not proof that 2,500 mg is safe for every active. If the previous product is a highly potent compound, sensitizer or genotoxic hazard, a fixed 10 ppm rule may be much too permissive. If the product is very low potency and the analytical method is highly sensitive, it may also be unnecessarily restrictive.
What is the therapeutic-dose criterion?
The therapeutic-dose method is a legacy dose-based approach. A commonly cited version limits exposure to no more than one-thousandth of the previous product's minimum daily therapeutic dose in the maximum daily dose of the next product. The exact dose definitions, routes and units must be written in the site's procedure before calculation.
Illustrative example: previous-product minimum therapeutic dose = 20 mg/day; next-product batch = 100 kg (100,000,000 mg); next-product maximum daily dose = 2,000 mg/day.
This method can be useful as a historical cross-check, but it may not represent hazards such as sensitization, genotoxicity, reproductive toxicity or local irritation. A therapeutic dose also may not exist for an intermediate, impurity, degradant or development compound.
What is an HBEL, PDE or ADE limit?
A health-based exposure limit (HBEL) is a scientifically justified exposure threshold intended to protect people from adverse effects. Permitted daily exposure (PDE) and acceptable daily exposure (ADE) are commonly used numerical expressions of that concept. The report should state the term used, units, route, population, critical effect, point of departure, uncertainty factors, limitations and approval status.
HBEL
Umbrella concept
Describes the health-based framework used to identify and control cross-contamination risk.
PDE
Permitted daily exposure
Reports an acceptable daily amount derived from pharmacological and toxicological evidence.
ADE
Acceptable daily exposure
Another widely used expression for a daily exposure unlikely to cause an adverse effect under defined conditions.
MACO
Carryover translation
Converts the approved PDE or ADE into a product-pair and equipment-specific residue mass.
EMA describes HBELs as a basis for risk identification in shared facilities. FDA API GMP guidance similarly expects residue limits to consider potency, toxicity and stability. These concepts support a risk-based program; they do not remove the need for validated cleaning and documented controls.
How a PDE or ADE is established
A qualified toxicologist reviews the complete evidence package and selects a scientifically appropriate point of departure. The report then applies justified adjustment factors and route considerations. The result is a documented health-based value—not a number copied from a generic table.
- Clinical pharmacology, therapeutic index and adverse effects
- Repeat-dose, chronic and local toxicity
- Genotoxicity, carcinogenicity and mutagenicity
- Reproductive and developmental toxicity
- Mechanism of action and critical target organ
- Human pharmacokinetics and relevant exposure routes
- NOAEL, LOAEL or another justified point of departure
- Metabolites, impurities, degradants and residual solvents
- Sensitization, allergy and high-potency concerns
- Species differences and sensitive populations
- Uncertainty, modifying and route-adjustment factors
- Data gaps, assumptions, review date and approval signatures
The formula above is educational and is not a universal toxicology calculator. Different substances and routes may require different approaches. The approved report and its scientific rationale control the value.
Worked comparison: one product pair, three approaches
Assume a next-product minimum batch of 100 kg, a next-product maximum daily dose of 2,000 mg/day, and shared equipment with 200,000 cm² of product-contact surface. For illustration, the previous product has a minimum therapeutic dose of 20 mg/day and an approved HBEL/PDE of 0.001 mg/day.
| Criterion | Calculation | Result | Interpretation |
|---|---|---|---|
| 10 ppm | 10 mg/kg × 100 kg | 1,000 mg | Concentration-based result |
| Therapeutic dose | (20 × 100,000,000) ÷ (1,000 × 2,000) | 1,000 mg | Legacy dose-based result |
| HBEL/PDE | (0.001 × 100,000,000) ÷ 2,000 | 50 mg | Health-based result; most protective in this example |
The numerical comparison shows why one familiar rule cannot be assumed safe for every active. In this fictional example, the HBEL-derived MACO is 20 times lower than the other two results. The approved site procedure should define how competing criteria are evaluated and how the scientifically protective value is selected; do not average criteria or change the HBEL to fit an analytical method.
Recovery correction, dilution, sample volume, reporting units and method capability must be included before this becomes a final laboratory acceptance criterion.
Why fixed limits can mislead
| Potential problem | Why it matters | Better control |
|---|---|---|
| Potency varies widely | The same 10 ppm concentration can represent very different patient exposures. | Use a qualified HBEL/PDE/ADE and product-pair MACO. |
| Non-dose-related hazards | Sensitizers or genotoxic substances may cause concern at very small exposures. | Obtain specialist toxicology and assess dedication or containment. |
| Therapeutic dose is unclear | Intermediates, impurities and development products may have no meaningful dose. | Use substance-specific hazard assessment and a justified marker. |
| Route is ignored | Oral, inhaled, dermal, parenteral and intrathecal exposure may not be equivalent. | Document route-specific reasoning in the HBEL report. |
| Analytical method is weak | A pass result above the true risk limit can create false assurance. | Set LOQ below the final limit and validate recovery at the target level. |
When can 10 ppm or therapeutic dose still be useful?
Legacy criteria may be retained as a documented supplemental check, a conservative floor, a historical comparison or a temporary screening tool while toxicological work is completed. They should not silently override a more protective health-based value. The rationale should be approved by Quality and supported by product knowledge.
HBEL-based cleaning-validation workflow
Define the scope
List products, strengths, routes, equipment trains, campaign patterns and potential residues.
Obtain the approved HBEL
Use a current toxicology report with route, units, rationale, reviewer and revision status.
Select worst cases
Consider potency, toxicity, solubility, cleanability, batch size, dose and residue persistence.
Calculate MACO and surfaces
Translate the value into equipment, surface, swab and rinse criteria using controlled units.
Confirm method capability
Verify specificity, recovery, precision, LOQ, blanks, sample stability and reporting rules.
Validate and monitor
Execute worst-case cleaning studies, document results, trend verification and review changes.
Use the controlled SOP system to assign responsibilities, approvals, training, review frequency and record retention.
Acceptance criteria beyond the numerical limit
Even a well-derived HBEL does not replace other release criteria. A cleaning-validation protocol should define all relevant controls and explain how they work together.
| Control | Purpose | Typical evidence |
|---|---|---|
| Previous-product residue | Controls chemical carryover against the selected MACO. | Specific swab, rinse or justified marker assay. |
| Visual cleanliness | Detects visible residue, pooling, fibers or foreign matter. | Trained inspection under defined lighting and access. |
| Detergent or solvent residue | Prevents cleaning agents from affecting the next product. | Specific assay, conductivity, TOC or justified limit. |
| Microbial and endotoxin controls | Controls contamination that a chemical assay may not detect. | Bioburden, objectionable-organism, endotoxin or hold-time evidence. |
| Cleaning-process parameters | Shows the validated recipe was actually executed. | Time, temperature, flow, pressure, concentration and cycle records. |
Sampling and analytical calculations
A low HBEL-derived limit can expose weaknesses in sampling and laboratory methods. Design the method around the final acceptance limit, not around an easy-to-measure concentration.
- Set LOQ below the final surface or sample limit.
- Demonstrate recovery on each relevant surface material.
- Define swab area, solvent, extraction and sample volume.
- Use rinse sampling for inaccessible paths only with a representativeness rationale.
- Include blanks, controls and sample stability.
- Identify worst-case locations and hard-to-clean parts.
- State whether results are raw or recovery-corrected.
- Control dilution, conversion and rounding rules.
- Define below-LOQ, invalid and atypical-result handling.
- Trend routine verification against the same approved limit.
Do not increase a health-based limit merely because the laboratory cannot achieve the required LOQ. Improve the method, revise a scientifically justified sampling strategy, select a suitable marker, redesign the equipment or evaluate dedication.
Choosing the approach for common situations
| Situation | Recommended direction | Documented decision |
|---|---|---|
| Approved HBEL available | Use it as the primary health-based input for risk and carryover calculations. | Link toxicology report, MACO, analytical method and protocol. |
| No HBEL yet | Use an interim, qualified risk assessment while obtaining toxicology; do not make the interim method permanent by default. | Owner, due date, assumptions, review and escalation. |
| Highly potent or sensitizing product | Assess containment, closed transfer, disposable parts or dedicated equipment. | Risk assessment, occupational and patient protection rationale. |
| HBEL below method capability | Improve analytical capability or reconsider the equipment arrangement. | Method-development evidence and change-control decision. |
| Different routes or vulnerable patients | Request route-specific toxicology and avoid copying an oral value to another route. | Applicability statement in the approved report. |
Equipment qualification and shared-facility controls
The calculated limit must be achievable on the real equipment. Connect surface area, materials, dead legs, access, drainage, automation, containment and cleaning recipes to the qualification lifecycle.
PQ and cleaning-validation studies demonstrate that the qualified equipment and process consistently meet the selected criteria during actual use.
Data integrity, changes and CAPA
PDE, ADE, MACO and HBEL decisions often pass through toxicology reports, spreadsheets, laboratory systems and electronic quality records. Apply ALCOA+ to source data, formulas, approvals, audit trails and revision history.
- Retain the original toxicological sources and approved report revision.
- Protect calculation formulas, input cells, units and conversion factors from uncontrolled edits.
- Record who entered, reviewed and approved each value and when.
- Assess applicable 21 CFR electronic-record and signature controls.
- Route failures, unexplained trends and systemic gaps through CAPA and the approved CAPA procedure.
Review the limit after new toxicology, impurities, routes, formulations, strengths, patient populations, products, equipment, detergents, cleaning parameters, methods or adverse trends. A change to a PDE or ADE may require recalculation, revalidation or a shared-facility decision.
Audit checklist for 10 ppm, therapeutic-dose and HBEL limits
- Every shared-facility substance has an HBEL status or documented rationale.
- The toxicology report identifies author, reviewer, date, route and revision.
- Point of departure and adjustment factors are explained.
- MACO traces to the approved value and correct product pair.
- 10 ppm or therapeutic-dose use is justified as primary or supplemental.
- Special hazards and dedication decisions are addressed.
- LOQ, recovery and sampling support the final criteria.
- Visual, microbial and detergent controls remain in place.
- Equipment surface area and cleanability evidence are current.
- Electronic calculations meet ALCOA+ and 21 CFR expectations.
- Review, change-control and revalidation triggers are defined.
- Failures and trends are linked to CAPA and effectiveness checks.
Frequently asked questions
Is 10 ppm a mandatory FDA cleaning-validation limit?
No. FDA inspection material discusses 10 ppm, a fraction of therapeutic dose and no visible residue as examples used in industry. Firms are expected to justify practical, achievable and verifiable limits based on the materials and process.
Does an HBEL replace the 10 ppm rule?
Where a qualified HBEL is available, it normally provides the more substance-specific health basis. A 10 ppm value may remain a supplemental cross-check, but it should not override a more protective, scientifically justified limit.
What is the difference between therapeutic dose and HBEL?
Therapeutic dose uses a pharmacological dose relationship, often a historical 1/1000 rule. HBEL uses toxicological and pharmacological evidence to estimate an exposure unlikely to cause harm, including hazards that dose-based rules may miss.
How is a 10 ppm MACO calculated?
On a mass basis, multiply 10 mg/kg by the minimum batch size of the next product in kilograms. Convert the result to surface, swab or rinse limits using the equipment area and sampling plan.
How is therapeutic-dose MACO calculated?
A commonly used legacy formula multiplies the previous product's minimum daily therapeutic dose by the next batch mass, then divides by 1,000 times the next product's maximum daily dose. The site's procedure must define the dose terms and units.
What does PDE or ADE contribute to cleaning validation?
The approved PDE or ADE supplies a health-based daily exposure value. Validation combines it with the next product's batch size and maximum daily dose to calculate a product-pair MACO.
Can “no visible residue” be the only criterion?
No. Visual inspection is important but cannot demonstrate absence of sub-visible chemical residue. Use it with health-based chemical criteria and applicable detergent, microbial and process controls.
What if the HBEL-derived limit is below the analytical LOQ?
Do not raise the acceptance limit to match the LOQ. Improve the method, validate recovery, revise a justified marker or sampling approach, redesign the equipment or assess dedication.
When should the HBEL or PDE report be reviewed?
Review it when new safety data, adverse signals, impurities, degradants, routes, formulations, patient populations, products, equipment, cleaning methods or regulatory expectations change.
Who should approve the final limit strategy?
A qualified toxicologist should lead health-based derivation, while Quality approves the controlled rationale and Validation, QC, Production and Engineering confirm that the limit is measurable and achievable in actual operation.
Conclusion
10 ppm, therapeutic dose and HBEL limits compared shows why cleaning validation cannot rely on one familiar number. Ten ppm is concentration-based, therapeutic dose is a historical pharmacological approach, and HBEL/PDE/ADE connects the limit to substance-specific health evidence.
A defensible program uses the current qualified toxicological value, converts it correctly into MACO and surface limits, verifies analytical capability, controls visual and microbial risks, and reviews the decision throughout the equipment lifecycle. Link the calculation to your Cleaning Validation in Pharmaceuticals program and keep the rationale traceable within the site's cGMP quality system.
Further reading
- FDA: Validation of Cleaning Processes inspection guide
- FDA: Q7A GMP guidance for active pharmaceutical ingredients
- EMA: Health-based exposure limits for shared facilities
.webp)
